Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Leukemia Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Leukemia

Protocol Alliance A041501
Cancer Type: NEWLY DIAGNOSED PRECURSOR B-CELL ALL
Fast Facts

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AAML1831
Cancer Type: de nova AML
Fast Facts

COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Patients must be less than 22 years of age at the time of study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1318
Cancer Type: (Ph-) ALL
Fast Facts

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A041701
Cancer Type: ACUTE MYELOID LEUKEMIA
Fast Facts

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A041702
Cancer Type: Chronic Lymphocytic Leukemia (CLL)
Fast Facts

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 YEARS OF AGE) with Chronic Lymphocytic Leukemia (CLL)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1712
Cancer Type: Chronic Myeloid Leukemia (CML)
Fast Facts

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NHLBI-MDS
Cancer Type: Myelodysplastic Syndromes
Fast Facts

The National Myelodysplastic Syndromes (MDS) Study

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AALL15P1
Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Fast Facts

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Infants Less than 1 Year of Age on the Date of Diagnosis are Eligible; Infants must be >36 Weeks Gestational Age at the Time of Enrollment.

Protocol COG AALL1621
Cancer Type: Relapsed Refractory CD22 B-ALL
Fast Facts

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

Protocol COG AALL1521
Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Fast Facts

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Age ≥ 1 Year and ≤ 21 Years at Time of Leukemia Diagnosis.

Protocol COG AALL1631
Cancer Type: Ph+ ALL
Fast Facts

International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Age:  > 1 Year and < 21 Years at ALL Diagnosis

Protocol COG ACCL16N1CD
Cancer Type: Acute Lymphoblastic Leukemia (ALL)

Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Protocol COG AALL1731
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS)

Protocol COG AALL1732
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Patients must be > 365 Days and < 25 Years of Age

Protocol COG AAML1531
Cancer Type: AML
Fast Facts

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Children with Down Syndrome > 90 Days and < 4 Years of Age at Diagnosis of AML or Myelodysplastic Syndrome (MDS) 

Protocol COG AALL1821
Cancer Type: B-ALL
Fast Facts

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Enrollment to Group 2/3 Stratum on AALL1821 has been temporarily closed to accrual as of March 22nd, 2021.

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.